Alexandria Real Estate Equities
A U.S. real estate investment trust specializing in laboratory, office, and research campuses for life-science and technology organizations.
Last updated August 21, 2026
AI crawler reads
No AI crawler has read this profile since Oct 28, 2026.
Overview
Alexandria Real Estate Equities, Inc. is a U.S.-based real estate investment trust focused on properties used by life-science, biotechnology, pharmaceutical, healthcare, agtech, and advanced-technology organizations. Rather than operating as a broad office landlord, Alexandria concentrates on specialized laboratory, research, and office environments that require technical infrastructure, flexible floor plans, high power and ventilation capacity, and proximity to universities, research hospitals, venture capital, and other innovation resources. The company develops, owns, redevelops, manages, and leases properties in major U.S. life-science and technology clusters. Its principal markets include the Boston-Cambridge area, the San Francisco Bay Area, San Diego, New York City, Seattle, Maryland, and Research Triangle markets. Alexandria’s portfolio has included large urban and university-adjacent campuses such as the Alexandria Center for Life Science in Manhattan, Alexandria Center at Kendall Square, and Technology Square in Cambridge, Massachusetts. These projects combine laboratory and office space with amenities and shared environments intended to support scientific collaboration and tenant recruitment. Alexandria’s business model is closely linked to the health of the life-sciences industry. Demand for its properties is influenced by biotechnology and pharmaceutical research activity, venture-capital availability, public and private research funding, drug-development cycles, and the financial condition of smaller emerging companies. The company has therefore sought to serve both established corporations and developing research firms, while using long-term leases, campus development, redevelopment, and tenant improvements to build durable relationships with occupants. In addition to its real-estate activities, Alexandria operates Alexandria Venture Investments, a venture-capital arm that invests in life-sciences companies. This gives the company exposure to the innovation ecosystem beyond property ownership, although its principal business remains real-estate investment and operations. Alexandria is named after Alexandria, Egypt, reflecting the city’s historical association with scholarship and science. The company became publicly traded through an initial public offering in 1997 that raised $155 million. Its shares trade on the New York Stock Exchange under the ticker symbol ARE. According to the company information summarized in the cited Wikipedia reference, as of December 31, 2024, Alexandria owned or held investments in 391 properties comprising approximately 44.1 million square feet. Its specialized portfolio and concentration in research clusters distinguish it from diversified office and industrial REITs, while also exposing it to sector-specific risks, including changes in research financing and laboratory demand.
History
The origins of Alexandria Real Estate Equities trace to an early-1990s proposal to create a real estate investment trust dedicated to biotechnology properties. In 1993, Jacobs Engineering Group partner Jerry M. Sudarsky was presented with a business plan prepared by Kendell R. Lang under the name BioProperties Management Group. The proposal envisioned a specialized landlord that would provide laboratories and offices to biotechnology companies, an approach that differed from the diversified office and commercial property models common at the time. The initial management group included Lang, Alan Gold, Gary Kreitzer, and Steven Stone. Jacobs Engineering invested $5 million in the venture and approached Joel S. Marcus, a lawyer and certified public accountant, to represent its interests and oversee the proposed management team. The company’s first acquisition consisted of four buildings in San Diego. This transaction established an early pattern for Alexandria: acquiring or developing properties in locations where scientific companies, universities, research institutions, and specialized labor were concentrated. San Diego was an important biotechnology market, and laboratory-oriented buildings offered a way to serve tenants whose requirements were not well met by conventional office properties. Alexandria was founded as a specialized REIT in 1994 and expanded its portfolio through acquisitions, development, redevelopment, and leasing. Over time, it broadened its focus from biotechnology properties to a wider group of life-science and technology users, including pharmaceutical companies, healthcare organizations, agtech businesses, and advanced-technology firms. The company generally favored locations near universities and research centers, where tenants could recruit scientific talent and maintain relationships with academic and clinical institutions. In 1997, Alexandria became a public company through an initial public offering that raised $155 million. Public-market access supported the company’s ability to assemble larger portfolios and pursue major campus projects. Its subsequent development activities included prominent properties in leading U.S. innovation districts, including the Alexandria Center for Life Science in Manhattan and large Cambridge, Massachusetts, projects such as Alexandria Center at Kendall Square and Technology Square. These properties combined laboratory and office uses and were designed around the infrastructure, amenities, and location requirements of research-oriented tenants. As the U.S. life-sciences sector grew, Alexandria positioned itself as an owner and developer of purpose-built research environments rather than merely a provider of generic office space. Laboratory conversion and construction can require substantial capital, technical expertise, and coordination with tenants, making property customization and campus operations important parts of the company’s model. Alexandria also developed Alexandria Venture Investments, which invests in life-sciences businesses and connects the company with the venture-backed innovation economy. The company’s growth has remained dependent on conditions in the life-sciences industry. Biotechnology and pharmaceutical research activity, public and private funding, venture capital, clinical-development pipelines, and the financial health of emerging companies can all affect leasing demand and tenant expansion. The company has also been described as having exposure to U.S. government funding of scientific research. By December 31, 2024, the cited reference reported that Alexandria owned or held investments in 391 properties totaling approximately 44.1 million square feet. It remains a publicly traded REIT headquartered in Pasadena, California, with operations concentrated in major U.S. life-science and technology markets.
- 2024
Portfolio reported at 391 properties
[1]As of December 31, 2024, the company was reported to own or hold investments in 391 properties containing approximately 44.1 million square feet.
- 1997
Initial public offering
[1]Alexandria became a public company through an initial public offering that raised $155 million.
- 1994
Company founded
[1]Alexandria Real Estate Equities was established as a specialized real estate investment trust focused on biotechnology and related research properties.
- 1994
First property acquisition
[1]The company’s first acquisition consisted of four buildings in San Diego, establishing its early laboratory-property platform.
- 1993
Biotechnology-property business plan developed
[1]Kendell R. Lang prepared a plan for BioProperties Management Group, a proposed REIT dedicated to providing laboratory and office space for biotechnology companies.
Products and positioning
A specialized life-science and technology real estate investment trust providing laboratory, research, office, and campus environments near leading universities and innovation ecosystems.
Specialized REIT properties
Life-science properties
Laboratory, research-office, and related facilities for biotechnology, pharmaceutical, healthcare, and other life-science organizations. These properties typically require specialized mechanical systems, laboratory infrastructure, technical utilities, and adaptable layouts. Alexandria’s portfolio is concentrated in major U.S. research clusters and often places properties near universities, hospitals, and scientific institutions.
Specialized REIT properties
Agtech properties
Research and office environments serving agricultural technology, food technology, and related innovation companies. These assets extend Alexandria’s science-oriented real-estate strategy beyond traditional biotechnology and connect its property platform with emerging research and production ecosystems.
Specialized REIT properties
Advanced-technology properties
Office, research, and development facilities for advanced-technology organizations. These properties complement Alexandria’s life-science portfolio and are intended for tenants whose operations require access to specialized talent, research institutions, and technology-focused business communities.
Life-science campus
Alexandria Center for Life Science
A major Alexandria life-science campus in Manhattan containing laboratory and office space for research-oriented tenants. The property is part of the company’s strategy of developing prominent, university- and institution-adjacent environments intended to attract biotechnology, pharmaceutical, and healthcare organizations.
Life-science campus
Alexandria Center at Kendall Square
A large laboratory and office campus in Cambridge, Massachusetts, within the Kendall Square innovation district. The project supports Alexandria’s presence in the Boston-area life-science market and reflects its emphasis on dense research ecosystems and proximity to universities and technology companies.
Technology and life-science campus
Technology Square
A substantial Cambridge, Massachusetts, technology and research property associated with Alexandria’s Boston-area portfolio. It provides space for technology and life-science users in a university-linked innovation district.
Venture capital
Alexandria Venture Investments
Alexandria’s venture-capital arm invests in life-sciences companies. It provides the company with an investment presence in the biotechnology and healthcare innovation ecosystem in addition to its core activities as a property owner, developer, and landlord.
Recent events
Alexandria Real Estate Equities prices public share offering[4]
Reported:
Alexandria Real Estate Equities announced the pricing of an upsized public offering of 7 million common shares at $210 per share and granted underwriters a 30-day option to purchase up to 1.05 million additional shares. The offering was expected to close on or about January 7, 2022, subject to customary conditions.
- Unconfirmed
Clarion acquires 70% interest in 400 Dexter[5]
Reported:
Clarion Partners acquired a 70 percent interest in Alexandria Real Estate Equities’ life science asset at 400 Dexter in Seattle. The deal valued the asset at $364 million.
Sources5 sources
Cite this profile: Cite the canonical profile. /brand-wiki/alexandria-real-estate-equities · Editorial policy · How profiles are compiled